Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Sarcopenia is associated with liver fibrosis in patients with nonalcoholic fatty liver disease and chronic hepatitis B. We investigated the association between sarcopenia and hepatic fibrotic burden in patients with type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM who had received a comprehensive medical health checkup were recruited. Muscle mass was assessed using computed tomography. Fibrotic burden was assessed using the fibrosis-4 index (FIB-4). The study population was divided by quartile stratification of the lumbar skeletal muscle index (LSMI). Results: Among 309 patients with T2DM, 75 (24.3%) had sarcopenia. These patients were significantly older and had higher FIB-4, whereas they had significantly lower body mass index (BMI) and LSMI than patients without sarcopenia (all p<0.05). The LSMI showed a significant negative correlation with the FIB-4 when analyzed in terms of quartile stratification (p=0.003). Multivariate analysis showed that female sex and higher BMI were independently associated with a reduced risk of sarcopenia (odds ratio [OR], 0.388; 95% confidence interval [CI], 0.199 to 0.755 and OR, 0.704; 95% CI, 0.618 to 0.801; all p<0.05), whereas a higher FIB- 4 was independently associated with an increased risk of sarcopenia (OR, 1.817; 95% CI, 1.180 to 2.797; p=0.007). Among patients with a BMI <25 kg/m2 (n=165), those with sarcopenia (n=54, 32.7%) had a significantly higher FIB-4 than those without (n=111, 67.3%; 1.66 vs 1.38, p=0.004). Conclusions: Sarcopenia is independently associated with fibrotic burden in patients with T2DM. Further studies should investigate whether the improvement of sarcopenia can ameliorate liver fibrosis in patients with T2DM.
Abstract
Background/Aims: Sarcopenia is associated with liver fibrosis in patients with nonalcoholic fatty liver disease and chronic hepatitis B. We investigated the association between sarcopenia and hepatic fibrotic burden in patients with type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM who had received a comprehensive medical health checkup were recruited. Muscle mass was assessed using computed tomography. Fibrotic burden was assessed using the fibrosis-4 index (FIB-4). The study population was divided by quartile stratification of the lumbar skeletal muscle index (LSMI). Results: Among 309 patients with T2DM, 75 (24.3%) had sarcopenia. These patients were significantly older and had higher FIB-4, whereas they had significantly lower body mass index (BMI) and LSMI than patients without sarcopenia (all p<0.05). The LSMI showed a significant negative correlation with the FIB-4 when analyzed in terms of quartile stratification (p=0.003). Multivariate analysis showed that female sex and higher BMI were independently associated with a reduced risk of sarcopenia (odds ratio [OR], 0.388; 95% confidence interval [CI], 0.199 to 0.755 and OR, 0.704; 95% CI, 0.618 to 0.801; all p<0.05), whereas a higher FIB- 4 was independently associated with an increased risk of sarcopenia (OR, 1.817; 95% CI, 1.180 to 2.797; p=0.007). Among patients with a BMI <25 kg/m2 (n=165), those with sarcopenia (n=54, 32.7%) had a significantly higher FIB-4 than those without (n=111, 67.3%; 1.66 vs 1.38, p=0.004). Conclusions: Sarcopenia is independently associated with fibrotic burden in patients with T2DM. Further studies should investigate whether the improvement of sarcopenia can ameliorate liver fibrosis in patients with T2DM.
참고문헌 (38)
- Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on Sarcopenia in Older People", Age Ageing, 39, pp.412~423 (2010)
- Chen LK, "Sarcopenia in Asia : consensus report of the Asian Working Group for Sarcopenia", J Am Med Dir Assoc, 15, pp.95~101 (2014)
- Itoh S, "Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience", Hepatol Res, 46, pp.292~297 (2016)
- The Lancet Diabetes Endocrinology, "Sarcopenia : a fate worth challenging", Lancet Diabetes Endocrinol, 2, pp.183~ (2014)
- Kim TN, "Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes : the Korean Sarcopenic Obesity Study(KSOS)", Diabetes Care, 33, pp.1497~1499 (2010)
- Stephen WC, "Sarcopenic-obesity and cardiovascular disease risk in the elderly", J Nutr Health Aging, 13, pp.460~466 (2009)
- Lim S, "Sarcopenic obesity : prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging(KLoSHA)", Diabetes Care, 33, pp.1652~1654 (2010)
- Cruz-Jentoft AJ, "Understanding sarcopenia as a geriatric syndrome", Curr Opin Clin Nutr Metab Care, 13, pp.1~7 (2010)
- Rinella ME, "Nonalcoholic fatty liver disease : a systematic review", JAMA, 313, pp.2263~2273 (2015)
- Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : the Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
- Lee YH, "Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease : nationwide surveys(KNHANES 2008-2011)", Hepatology, 63, pp.776~786 (2016)
- Koo BK, "Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis", J Hepatol, 66, pp.123~131 (2017)
- Lee YH, "Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance : nationwide surveys(KNHANES 2008-2011)", J Hepatol, 63, pp.486~493 (2015)
- Han E, "Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B", Aliment Pharmacol Ther, 48, pp.300~312 (2018)
- American Diabetes Association, "Standards of medical care in diabetes:2014", Diabetes Care, 37(Suppl 1), pp.S14~S80 (2014)
- Baracos VE, "Body composition in patients with non-small cell lung cancer : a contemporary view of cancer cachexia with the use of computed tomography image analysis", Am J Clin Nutr, 91, pp.1133S~1137S (2010)
- Prado CM, "Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts : a population-based study", Lancet Oncol, 9, pp.629~635 (2008)
- American Diabetes Association, "Diagnosis and classification of diabetes mellitus", Diabetes Care, 37(Suppl 1), pp.S81~S90 (2014)
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection : comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
- Kim SU, "Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis", J Clin Gastroenterol, 43, pp.267~271 (2009)
- Chon YE, "Controlled attenuation parameter(CAP)for detection of hepatic steatosis in patients with chronic liver diseases : a prospective study of a native Korean population", Liver Int, 34, pp.102~109 (2014)
- Giusto M, "Sarcopenia in liver cirrhosis : the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry", Eur J Gastroenterol Hepatol, 27, pp.328~334 (2015)
- Hiraoka A, "Muscle atrophy as presarcopenia in Japanese patients with chronic liver disease : computed tomography is useful for evaluation", J Gastroenterol, 50, pp.1206~1213 (2015)
- Papatheodoridis GV, "Diabetes mellitus in chronic hepatitis B and C : prevalence and potential association with the extent of liver fibrosis", J Viral Hepat, 13, pp.303~310 (2006)
- Angulo P, "Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis", Hepatology, 30, pp.1356~1362 (1999)
- Liccini A, "Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus", J Am Med Dir Assoc, 17, pp.846~851 (2016)
- Choe EY, "Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes", J Gastroenterol Hepatol, 33, pp.1082~1091 (2018)
- Hanai T, "Sarcopenia impairs prognosis of patients with liver cirrhosis", Nutrition, 31, pp.193~199 (2015)
- Bugianesi E, "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease : sites and mechanisms", Diabetologia, 48, pp.634~642 (2005)
- Bhanji RA, "Sarcopenia in hiding : the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis", Hepatology, 66, pp.2055~2065 (2017)
- Kawaguchi T, "Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people : a pilot study", Appl Physiol Nutr Metab, 36, pp.276~283 (2011)
- Kawaguchi T, "Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD : a pilot study", J Gastroenterol, 46, pp.746~757 (2011)
- Janssen I, "Low relative skeletal muscle mass(sarcopenia)in older persons is associated with functional impairment and physical disability", J Am Geriatr Soc, 50, pp.889~896 (2002)
- Chung JY, "Body composition and its association with cardiometabolic risk factors in the elderly : a focus on sarcopenic obesity", Arch Gerontol Geriatr, 56, pp.270~278 (2013)
- Rolland Y, "Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women : the EPIDOS(EPIDemiologie de l’OSteoporose)Study", Am J Clin Nutr, 89, pp.1895~1900 (2009)
- Cetrone M, "Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II", Curr Diabetes Rev, 10, pp.231~237 (2014)
- Campins L, "Oral drugs related with muscle wasting and sarcopenia : a review", Pharmacology, 99, pp.1~8 (2017)